Use of 18F-HX4 PET/CT to estimate tumor hypoxia enrolled subjects from ongoing Phase 2 trials using tarloxotinib bromide in advanced NSCLC and SCCHN. This is an ASCO Meeting Abstract from the 2016 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback